Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in the Discovery of Selective JAK Inhibitors
Christel Menet, Luc Van Rompaey, Raphaël Geney
Progress in medicinal chemistry (2013), pp. 153-223
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
S P H Alexander, Helen E. Benson, Elena Faccenda, et al.
British Journal of Pharmacology (2013) Vol. 170, Iss. 8, pp. 1797-1867
Open Access | Times Cited: 428
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 207
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey, René Galien, Ellen M. van der Aar, et al.
The Journal of Immunology (2013) Vol. 191, Iss. 7, pp. 3568-3577
Closed Access | Times Cited: 204
Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
Andrea J. Gonzales, Jill Bowman, Gregory J. Fici, et al.
Journal of Veterinary Pharmacology and Therapeutics (2014) Vol. 37, Iss. 4, pp. 317-324
Open Access | Times Cited: 201
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 198
Tuberculosis and impaired IL-23–dependent IFN-γ immunity in humans homozygous for a common TYK2 missense variant
Stéphanie Boisson‐Dupuis, Noé Ramírez-Alejo, Zhi Li, et al.
Science Immunology (2018) Vol. 3, Iss. 30
Open Access | Times Cited: 183
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Silvio Danese, Matthew B. Grisham, Jennifer Hodge, et al.
AJP Gastrointestinal and Liver Physiology (2015) Vol. 310, Iss. 3, pp. G155-G162
Open Access | Times Cited: 158
Therapeutic approaches to asthma–chronic obstructive pulmonary disease overlap syndromes
Peter J. Barnes
Journal of Allergy and Clinical Immunology (2015) Vol. 136, Iss. 3, pp. 531-545
Closed Access | Times Cited: 154
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 3, pp. 1130-1152
Open Access | Times Cited: 141
Janus kinase inhibitors in dermatology: A systematic review
Rony Shreberk‐Hassidim, Yuval Ramot, Abraham Zlotogorski
Journal of the American Academy of Dermatology (2017) Vol. 76, Iss. 4, pp. 745-753.e19
Closed Access | Times Cited: 140
The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression
Cheng-lin Luo, Yu-qiong Liu, Peng Wang, et al.
Biomedicine & Pharmacotherapy (2016) Vol. 82, pp. 595-605
Closed Access | Times Cited: 120
Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease
Peter J. Barnes
Pharmacological Reviews (2016) Vol. 68, Iss. 3, pp. 788-815
Open Access | Times Cited: 106
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
Kim Papp, David M. Pariser, Mary Catlin, et al.
British Journal of Dermatology (2015) Vol. 173, Iss. 3, pp. 767-776
Open Access | Times Cited: 105
Development of Selective Covalent Janus Kinase 3 Inhibitors
Li Tan, Koshi Akahane, Randall McNally, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 16, pp. 6589-6606
Open Access | Times Cited: 103
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1398-1398
Open Access | Times Cited: 10
Genetics of Psoriasis and Pharmacogenetics of Biological Drugs
Rocío Prieto‐Pérez, Teresa Cabaleiro, E. Daudén, et al.
Autoimmune Diseases (2013) Vol. 2013, pp. 1-13
Open Access | Times Cited: 77
Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors
Minjian Yang, Bingzhong Tao, Chengjuan Chen, et al.
Journal of Chemical Information and Modeling (2019) Vol. 59, Iss. 12, pp. 5002-5012
Closed Access | Times Cited: 54
Selectivity and Ranking of Tight-Binding JAK-STAT Inhibitors Using Markovian Milestoning with Voronoi Tessellations
Anupam Anand Ojha, Ambuj Srivastava, Lane Votapka, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 8, pp. 2469-2482
Open Access | Times Cited: 18
VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease
Sudipta Mahajan, James K. Hogan, Dina Shlyakhter, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 353, Iss. 2, pp. 405-414
Closed Access | Times Cited: 59
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
Angelika Berger, Andrea Hoelbl‐Kovacic, Jérôme Bourgeais, et al.
Leukemia (2013) Vol. 28, Iss. 3, pp. 629-641
Open Access | Times Cited: 58
Tofacitinib for the treatment of ulcerative colitis
A Fernández-Clotet, Jesús Castro‐Poceiro, Julián Panés
Expert Review of Clinical Immunology (2018) Vol. 14, Iss. 11, pp. 881-892
Closed Access | Times Cited: 54
Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts
Xiaodong Ma, Xiaoqing Lv, Jiankang Zhang
European Journal of Medicinal Chemistry (2017) Vol. 143, pp. 449-463
Closed Access | Times Cited: 53
Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
Qibin Su, Erica Banks, Geraldine Bebernitz, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 9, pp. 4517-4527
Closed Access | Times Cited: 46
Revealing innovative JAK1 and JAK3 inhibitors: a comprehensive study utilizing QSAR, 3D-Pharmacophore screening, molecular docking, molecular dynamics, and MM/GBSA analyses
Abdelmoujoud Faris, Ivana Cacciatore, Radwan Alnajjar, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 5
Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
Heying Pei, Linhong He, Mingfeng Shao, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top